CXCR4 and cancer: Thus, the repeated dose administration at the CXCR4 expression peak in tumors (q3d) achieved our goal of maintaining the CXCR4+ CCF absent, or low, leading to a complete elimination of Mets (achieving, therefore, a complete elimination of CXCR4+ cancer cells) in a portion of mice, in both cell line and patient‐derived CCR models.